LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase)

News alerts, weekly reports and conference planners

Entrez ID:

LYN mutation	Non Small Cell Lung Cancer	LYN mutation	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
LYN mutation	Melanoma	LYN mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
NCOR1-LYN fusion	B Acute Lymphoblastic Leukemia	NCOR1-LYN fusion	B Acute Lymphoblastic Leukemia	dasatinib Sensitive: C4 – Case Studies dasatinib Sensitive : C4	dasatinib Sensitive: C4 – Case Studies dasatinib Sensitive : C4
NCOR1-LYN fusion	B Acute Lymphoblastic Leukemia	NCOR1-LYN fusion	B Acute Lymphoblastic Leukemia	sirolimus Resistant: D – Preclinical sirolimus Resistant : D	sirolimus Resistant: D – Preclinical sirolimus Resistant : D
LYN overexpression + FLT3-ITD mutation	Acute Myelogenous Leukemia	LYN overexpression + FLT3-ITD mutation	Acute Myelogenous Leukemia	dasatinib Resistant: D – Preclinical dasatinib Resistant : D	dasatinib Resistant: D – Preclinical dasatinib Resistant : D

Associations(5)